NCT00720798 · OUTCOME
Erythrocyte Sedimentation Rate at Baseline and Weeks 24, 48, 108, 156, 204, and 264
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies · Source last updated 2014-09-30
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- mm/h
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline to Week 264
What was measured
Erythrocyte sedimentation rate (ESR) was determined locally.
Analysis population: All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.
Groups in this outcome
Tocilizumab
Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Tocilizumab | 2067 |
|---|
Reported measurements
Baseline (n = 2047)
Values in mm/h · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tocilizumab | 46.2 | 27.45 | Not reported | Not reported | Not reported |
|---|
Week 24 (n = 1992)
Values in mm/h · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tocilizumab | 11.3 | 14.97 | Not reported | Not reported | Not reported |
|---|
Week 48 (n = 1830)
Values in mm/h · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tocilizumab | 10.2 | 13.94 | Not reported | Not reported | Not reported |
|---|
Week 108 (n = 1606)
Values in mm/h · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tocilizumab | 9.0 | 12.79 | Not reported | Not reported | Not reported |
|---|
Week 156 (n = 1509)
Values in mm/h · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tocilizumab | 8.9 | 12.44 | Not reported | Not reported | Not reported |
|---|
Week 204 (n = 1412)
Values in mm/h · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tocilizumab | 8.9 | 12.01 | Not reported | Not reported | Not reported |
|---|
Week 264 (n = 1329)
Values in mm/h · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tocilizumab | 9.7 | 13.51 | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 27.45
- value
- 46.2
- title
- Baseline (n = 2047)
- categories
- measurements
- group Id
- OG000
- spread
- 14.97
- value
- 11.3
- title
- Week 24 (n = 1992)
- categories
- measurements
- group Id
- OG000
- spread
- 13.94
- value
- 10.2
- title
- Week 48 (n = 1830)
- categories
- measurements
- group Id
- OG000
- spread
- 12.79
- value
- 9.0
- title
- Week 108 (n = 1606)
- categories
- measurements
- group Id
- OG000
- spread
- 12.44
- value
- 8.9
- title
- Week 156 (n = 1509)
- categories
- measurements
- group Id
- OG000
- spread
- 12.01
- value
- 8.9
- title
- Week 204 (n = 1412)
- categories
- measurements
- group Id
- OG000
- spread
- 13.51
- value
- 9.7
- title
- Week 264 (n = 1329)
- description
- Erythrocyte sedimentation rate (ESR) was determined locally.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.
- id
- OG000
- title
- Tocilizumab
- param Type
- MEAN
- population Description
- All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.
- time Frame
- Baseline to Week 264
- title
- Erythrocyte Sedimentation Rate at Baseline and Weeks 24, 48, 108, 156, 204, and 264
- type
- SECONDARY
- unit Of Measure
- mm/h
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle